Universität zu Köln

Journal Article

Bendell, Johanna C., Bischoff, Helge G., Hwang, Jimmy, Reinhardt, Hans Christian, Zander, Thomas, Wang, Xuejing, Hynes, Scott, Pitou, Celine, Campbell, Robert, Iversen, Philip, Farrington, Daphne L., Bell-McGuinn, Katherine and Thomas, Michael (2020). A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Invest. New Drugs, 38 (4). S. 1145 - 1156. DORDRECHT: SPRINGER. ISSN 1573-0646